ANDA 206058, held by Accord Healthcare. Ibandronate Sodium.
As of Nov 21, 2026, ANDA 206058 (Ibandronate Sodium), held by Accord Healthcare, was first approved by FDA on Feb 5, 2016, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 5, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 3MG BASE/3ML · injectable;intravenous | Ibandronate Sodium | Rx |
| Feb 3, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 25, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 12, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 5, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters